Cited by 394Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 156 of the 159 references it cites were found in a registry or an index.

Emerging diagnostics and therapeutics for Alzheimer disease

Self, Wade K., Holtzman, David M.·2023·Nature Medicine

DOI 10.1038/s41591-023-02505-2

Open this paper in CoChat — free account

Abstract

Alzheimer disease (AD) is the most common contributor to dementia in the world, but strategies that slow or prevent its clinical progression have largely remained elusive, until recently. This Review highlights the latest advances in biomarker technologies and therapeutic development to improve AD diagnosis and treatment. We review recent results that enable pathological staging of AD with neuroimaging and fluid-based biomarkers, with a particular emphasis on the role of amyloid, tau and neuroinflammation in disease pathogenesis. We discuss the lessons learned from randomized controlled trials, including some supporting the proposal that certain anti-amyloid antibodies slow cognitive decline during the mildly symptomatic phase of AD. In addition, we highlight evidence for newly identified therapeutic targets that may be able to modify AD pathogenesis and progression. Collectively, these recent discoveries-and the research directions that they open-have the potential to move AD clinical care toward disease-modifying treatment strategies with maximal benefits for patients.

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02505-2

Cites

156 of 156 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
Retracted
Lecanemab in early Alzheimer's disease
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212948 · Cited by 5,678
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
Nichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., Abdoli, A., Abualhasan, A., Abu-Gharbieh, E., Akram, T. T., et al. (2022) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00249-8 · Cited by 5,575
Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citation
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Self-citation
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059

Show all 159 references

Research works printed but not linked: 1

ALZFORUM. Gantenerumab mystery: how did it lose potency in phase 3? https://www.alzforum.org/news/conference-coverage/gantenerumab-mystery-how-did-it-lose-potency-phase-3

Sorted by citations

Items 101–200 of 394

Advancing Alzheimer's Therapy: Computational strategies and treatment innovations
Paul, J. K., Malik, A., Azmal, M., Gulzar, T., Afghan, M. T. R., Talukder, O. F., Shahzadi, S., & Ghosh, A. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.02.002 · Cited by 10
Ketamine’s Role in Neuroinflammation and Neuroprotection Across Neurological and Psychiatric Disorders: A Narrative Review
Silva, G. N., Brandão, V. G., Blum, K., Lewandrowski, K., & Fiorelli, R. K. A. (2025) · Pharmaceuticals · doi:10.3390/ph18091298 · Cited by 10
Reversing inflammatory diseases via trained immunity: mechanisms, challenges, and prospects
Xu, W., Guo, Z., Xu, T., Chen, J., Chen, L., & Xu, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1666233 · Cited by 14
Ferritin nanocage-enabled detection of pathological tau in living human retinal cells
Barolo, L., Gigante, Y., Mautone, L., Ghirga, S., Soloperto, A., Giorgi, A., Ghirga, F., Pitea, M., Incocciati, A., Mura, F., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-62188-8 · Cited by 10
Blood Cathepsins on the Risk of Alzheimer's Disease and Related Pathological Biomarkers: Results from Observational Cohort and Mendelian Randomization Study
Qian, X., Ding, G.-Y., Chen, S.-Y., Liu, X.-L., Zhang, M., & Tang, H. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.107 · Cited by 10
ADAM10 isoforms: Optimizing usage of antibodies based on protein regulation, structural features, biological activity and clinical relevance to Alzheimer’s disease
Dorta, S., Alexandre-Silva, V., Popolin, C. P., de Sousa, D. B., Grigoli, M. M., Pelegrini, L. N. D. C., Manzine, P. R., Camins, A., Marcello, E. E., Endres, K., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102464 · Cited by 9
Caveolae with GLP-1 and NMDA Receptors as Crossfire Points for the Innovative Treatment of Cognitive Dysfunction Associated with Neurodegenerative Diseases
Nakashima, M., Suga, N., Yoshikawa, S., & Matsuda, S. (2024) · Molecules · doi:10.3390/molecules29163922 · Cited by 9
Identification of risk factors and development of a predictive nomogram for sarcopenia in Alzheimer's disease
Chen, S., Ou, R., Wei, Q., Fu, J., Zhao, B., Chen, X., & Shang, H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14503 · Cited by 9
Blood biomarker profiles in young-onset neurocognitive disorders: A cohort study
Bhalala, O. G., Beamish, J., Eratne, D., Summerell, P., Porter, T., Laws, S. M., Kang, M. J., Huq, A. J., Chiu, W.-H. M., Cadwallader, C. J., et al. (2025) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674241312805 · Cited by 9
Pitolisant alleviates brain network dysfunction and cognitive deficits in a mouse model of Alzheimer’s disease
Zou, Y., Yang, L., Zhu, J., Fan, J., Zheng, H., Liao, X., Yang, Z., Zhang, K., Jia, H., Konnerth, A., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03358-8 · Cited by 10
Sodium benzoate treatment decreased amyloid beta peptides and improved cognitive function among patients with Alzheimer’s disease: secondary analysis of a randomized clinical trial
Lin, H.-C., & Lane, H. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03492-3 · Cited by 9
Pathologic and Therapeutic Schwann Cells
Shurin, M. R., Wheeler, S., Zhong, H. M., & Zhou, Y. (2025) · Cells · doi:10.3390/cells14171336 · Cited by 9
Inducible deletion of DGAT1 and 2 from microglia exacerbates neurodegeneration and endolysosomal lipid accumulation in male PS19 mice
Tabor, G. T., Litvinchuk, A., Chen, Y., Allison, A., Sun, E. W., van Lengerich, B., Davis, S. S., West, E., Schlachetzki, J. C. M., Zeng, C., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2025.116841 · Cited by 14
Self-citation
Multi-Omic Blood Biomarkers as Dynamic Risk Predictors in Late-Onset Alzheimer’s Disease
Bhalala, O. G., Watson, R., & Yassi, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021231 · Cited by 10
In vitro and in silico investigation of FDA‐approved drugs to be repurposed against Alzheimer's disease
Akkaya, D., Seyhan, G., Sarı, S., & Barut, B. (2024) · Drug Development Research · doi:10.1002/ddr.22184 · Cited by 8
A bibliometric analysis of the relationship between traumatic brain injury and Alzheimer’s disease (1993-2023)
Hu, J., Zhang, X., Yang, H., Xu, Y., Zhang, M., & Niu, X. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1462132 · Cited by 8
Bioactivated Glucoraphanin Improves Cell Survival, Upregulating Phospho-AKT, and Modulates Genes Involved in DNA Repair in an In Vitro Alzheimer’s Disease Model: A Network-Transcriptomic Analysis
Minuti, A., Mazzon, E., Iori, R., Chiricosta, L., & Artimagnella, O. (2024) · Nutrients · doi:10.3390/nu16234202 · Cited by 9
Chemical exchange saturation transfer MRI for neurodegenerative diseases: An update on clinical and preclinical studies
Saiyisan, A., Zeng, S., Zhang, H., Wang, Z., Wang, J., Cai, P., & Huang, J. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-01246 · Cited by 10
Identification of a novel pyrrolo[2,3- b ]pyridine compound as a potent glycogen synthase kinase 3β inhibitor for treating Alzheimer’s disease
Xun, Q., Zhang, J., Feng, L., Ma, Y., Li, Y., & Shi, X. (2025) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2025.2466846 · Cited by 8
The role of TREM2 in myelin sheath dynamics: A comprehensive perspective from physiology to pathology
Que, X., Zhang, T., Liu, X. Y., Yin, Y., Xia, X., Gong, P., Song, W., Qin, Q., Xu, Q., & Tang, Y. (2025) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2025.102732 · Cited by 8
Multiplexed CRISPR Assay for Amplification-Free Detection of miRNAs
Silva, P. I. T. D., Hiniduma, K., Canete, R. C., Bhalerao, K. S., Shawky, S. M., Gunathilaka, H., Rouge, J. L., Mosa, I. M., Steffens, D. C., Manning, K. J., et al. (2025) · Biosensors · doi:10.3390/bios15060346 · Cited by 8
A label-free electrochemical immunosensor based on MWCNT-COOH/dPEDOT for early detection of Alzheimer's disease biomarker p-Tau 217
Ariyasajjamongkol, N., Thongwattana, N., Luechaipanit, W., Haethaisong, T., Chongsuksantikul, A., Oangkhana, P., Thanapornsangsuth, P., Paradee, N., Phasuksom, K., & Sirivat, A. (2025) · Journal of Electroanalytical Chemistry · doi:10.1016/j.jelechem.2025.119281 · Cited by 8
A functional neuroimaging biomarker of mild cognitive impairment using TD-fNIRS
Dubois, J., Duffy, J. G., Field, R. M., Koch, E. M., Aghajan, Z. M., Miller, N., Perdue, K. L., Sahagian, G. A., & Taylor, M. (2025) · npj Dementia · doi:10.1038/s44400-025-00018-y · Cited by 8
Using magnetic Pt/Os nanozyme to catalyze methylene blue urea derivative: A novel dual-mode strategy for the detection of acetylcholinesterase and inhibitors
Yu, X., Zhuang, W., Bai, W., Li, Q., Tan, H., Zhang, J., Yao, Y., Li, S., Bai, H., Sun, X., et al. (2025) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2025.138291 · Cited by 8
Amyloid-β-driven glymphatic dysfunction in Alzheimer’s disease model mice is driven by Ca2+-mediated increases in astrocytic cholesterol
Zhang, Z., Li, S., Xu, L., Xiao, S., Li, Y., Huang, J., Huang, J., Zuo, Y., Wen, W., Dai, Q., et al. (2026) · Nature Neuroscience · doi:10.1038/s41593-026-02261-9 · Cited by 9
Neuropathological stage‐dependent proteome mapping of the olfactory tract in Alzheimer 's disease: From early olfactory‐related omics signatures to computational repurposing of drug candidates
Cartas‐Cejudo, P., Cortés, A., Lachén‐Montes, M., Anaya‐Cubero, E., Puerta, E., Solas, M., Fernández‐Irigoyen, J., & Santamaría, E. (2024) · Brain Pathology · doi:10.1111/bpa.13252 · Cited by 8
Advancing Early Diagnostic Accuracy for Alzheimer s Disease Through the Integration of Machine and Deep Learning Paradigms by Applying Multisource Datasets
Kumari, R., Ahmad, T., Talaan, A., Gola, V., Das, S., & Singh, R. K. (2024) · Proceedings of international conference on intelligent systems and new applications. · doi:10.58190/icisna.2024.88 · Cited by 8
Identification of Molecular Correlations of GSDMD with Pyroptosis in Alzheimer's Disease
Song, T., Chen, Y., Li, C., Yao, Y., Ma, S., Yazhen, S., & Cheng, J. (2024) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073285497240226061936 · Cited by 9
Selective Orexin 2 Receptor Blockade Alleviates Cognitive Impairments and the Pathological Progression of Alzheimer’s Disease in 3xTg-AD Mice
Hu, X.-H., Yu, K.-Y., Li, X., Zhang, J., Jiao, J., Wang, Z.-J., Cai, H.-Y., Wang, L., He, Y., & Wu, M. (2024) · The Journals of Gerontology Series A · doi:10.1093/gerona/glae115 · Cited by 7
Blockade of brain alkaline phosphatase efficiently reduces amyloid-β plaque burden and associated cognitive impairment
Soria-Tobar, L., Román-Valero, L., Sebastián‐Serrano, Á., Aivar, P., Alvarez‐Castelao, B., & Dı́az-Hernández, M. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01600-x · Cited by 8
A single fibril study reveals that ApoE inhibits the elongation of Aβ42 fibrils in an isoform-dependent manner
Dasadhikari, S., Ghosh, S., Pal, S., Knowles, T. P. J., & Garai, K. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01524-z · Cited by 9
Advancements and challenges in using AI for biomarker detection in early Alzheimer’s disease
Beheshti, I., Albensi, B. C., Freitas, A. A., & Ghafourian, T. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104415 · Cited by 9
Special Issue: “New Trends in Alzheimer’s Disease Research: From Molecular Mechanisms to Therapeutics: 2nd Edition”
Cacabelos, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157175 · Cited by 8
AAV delivery of artificial miRNA targeting MAPT for the reduction of tau pathology in Alzheimer’s disease
Hogestyn, J. M., Wischhof, E., Chen, Y., Chan, T., Richards, B., Mahendran, T., Adams, J., Dubreuil, D., Bu, J., Jackson, R., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.052 · Cited by 7
Alzheimer's disease diagnosis and treatment: From pathophysiological insights to therapeutic advances in the era of precision neurology (2025 review)
Kim, M., Kwon, H., Sohn, S., Lee, W. J., Cho, K., & Kim, G. W. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251391820 · Cited by 12
Brain delivery of a neurotrophic peptide derived from secreted amyloid precursor protein APPsα as a therapeutic strategy for Alzheimer's disease
Rehra, L., Erdinger, S., Wagner, L., Baltissen, D., Just, J., König, L., Mühlberg, E., Eisenzapf, T., Kilian, L., Banićević, M., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114374 · Cited by 7
The role of the gut microbiome in the regulation of astrocytes in Alzheimer's disease
Chandra, S., & Vassar, R. J. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00425 · Cited by 7
Rational Design, Synthesis, and Evaluation of Rofecoxib-Based Photosensitizers for the NIR Imaging and Photo-Oxidization of Aβ Aggregates
Anwar, G., Cao, Y., Shi, W., Niu, L., & Yan, J. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00496 · Cited by 7
Evaluation of the Alkaloids as Inhibitors of Human Acetylcholinesterase by Molecular Docking and ADME Prediction
Negru, D. C., BUNGAU, S. G., Radu, A.-F., Ţiţ, D. M., Radu, A.-F., Nistor-Cseppento, C. D., & Negru, P. A. (2024) · In Vivo · doi:10.21873/invivo.13822 · Cited by 6
Investigation of patterns and associations of neuroinflammation in cognitive impairment
Gan, R., Xie, H., Zhao, Z., Wu, X., Wang, R., Wu, B., Chen, Q., & Jia, Z. (2025) · Cerebral Cortex · doi:10.1093/cercor/bhaf013 · Cited by 7
CD2AP at the junction of nephropathy and Alzheimer’s disease
Vandal, M., Janmaleki, M., Rea, I. M., Gunn, C., Hirai, S., Biernaskie, J. A., Chun, J., Gordon, G. R., Shaw, A. S., Sanati‐Nezhad, A., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00852-x · Cited by 9
Chiral Plasmonic Structures: From Intrinsically Optical Properties to Nanophotonic Applications
Wu, T. S., Luo, Z., Wang, H., Zhang, Z., Wang, G., & Bai, F. (2025) · ACS Materials Letters · doi:10.1021/acsmaterialslett.5c00465 · Cited by 6
Atractylenolide III Mitigates Alzheimer's Disease by Enhancing Autophagy via the YY1 ‐ TFEB Pathway
Zhang, X., Chu, S., Huang, Y., Li, Z., Song, J., Wang, P., Su, Y., Zhang, Z., & Xie, Z. (2025) · Phytotherapy Research · doi:10.1002/ptr.70069 · Cited by 6
Immunotherapies for Aging and Age-Related Diseases: Advances, Pitfalls, and Prospects
Yang, M., Wu, S., Zhang, J., Lu, L., Deng, D., Xia, Q., Lovell, J. F., Shi, X., & Jin, H. (2025) · Research · doi:10.34133/research.0866 · Cited by 7
Gut Microbiome Alterations in Mild Cognitive Impairment: Findings from the ALBION Greek Cohort
Rouskas, K., Mamalaki, E., Ntanasi, E., Pantoura, M., Anezaki, M., Emmanouil, C., Novau-Ferré, N., Bulló, M., Dimas, A. S., Papandreou, C., et al. (2025) · Microorganisms · doi:10.3390/microorganisms13092112 · Cited by 6
Neuroinflammatory suppression with protocatechuic acid attenuates Alzheimer’s disease phenotypes in 5 ×FAD transgenic mice
Kim, Y., Cho, M., Jeon, C., Goh, G., & Kim, M. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118598 · Cited by 6
Chitosan (Nano)formulations as Therapeutic Tools for Neurodegenerative Diseases: A Comprehensive Review
Gomes, A. C. C., Almeida, A., Freire, C. S. R., & Ferreira, B. J. M. L. (2025) · Polymers · doi:10.3390/polym17212838 · Cited by 6
Unrevealing role of TLRs/NLRP receptors in halting Alzheimer's neuroinflammation: Current progress and existing therapies
Upadhayay, S. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116285 · Cited by 7
Chemical Strategies to Modulate Amyloidogenesis Associated with Neurodegenerative Diseases
Na, C., Jang, Y., Son, M., & Lim, M. H. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c20362 · Cited by 6
Engineered microglial membrane-coated polydopamine-based nanomedicine for precise treatment of Alzheimer's disease
Huang, Q., Lv, Y. M., Ye, X. W., Xia, X., Chen, Y., Wang, X., Tong, F., Yang, W., Bozorov, K. A., Shevtsov, M. A., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114896 · Cited by 6
Introduction to Neurodegenerative Diseases
Seyedebrahimi, R., Yang, P., Azimzadeh, M., Farsani, M. E., Ababzadeh, S., Kalhor, N., & Sheykhhasan, M. (2024) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/979-8-3693-1281-0.ch002 · Cited by 6
Review of the Brain’s Behaviour after Injury and Disease for Its Application in an Agent-Based Model (ABM)
Irastorza-Valera, L., Gómez, E. S., Benítez, J. M., Montáns, F. J., & Saucedo‐Mora, L. (2024) · Biomimetics · doi:10.3390/biomimetics9060362 · Cited by 7
Cavity Lasing of Thioflavin T in the Condensed Phase for Discrimination between Surface Interaction and β-Sheet Groove Binding in Alzheimer-Linked Peptides
Hańczyc, P. (2024) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.4c01709 · Cited by 6
Altered Neuronal Activity Patterns of the Prefrontal Cortex in Alzheimer’s Disease After Transcranial Alternating Current Stimulation: A Resting-State fMRI Study
Wang, T., Yan, S., Shan, Y., Xing, Y., Bi, S., Chen, Z., Xi, H., Xue, H., Qi, Z., Tang, Y., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240400 · Cited by 6
An emerging role for the gut microbiome in tauopathy
Zhu, Y., Self, W. K., & Holtzman, D. M. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00423 · Cited by 6
Self-citation
Depletion of TDP-43 exacerbates tauopathy-dependent brain atrophy by sensitizing vulnerable neurons to caspase 3-mediated endoproteolysis of tau in a mouse model of Multiple Etiology DementiaPreprint
Baghel, M. S., Burns, G. D., Tsapatsis, M., Mallika, A. P., Cruz, A. L., Cao, T., Chen, X. K., Rosa, I. D. L., Marx, S. R., Ye, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.26.600814 · Cited by 6
Gut microbiome synthesizes important core metabolites to prevent cognitive decline and mitigate onset and progression of Alzheimer's disease
Al-Abbas, N. S., & Shaer, N. A. (2024) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823241309024 · Cited by 5
Unraveling the Role of Perivascular Macrophages in Alzheimer's Disease: Insights from the Crosstalk between Immunometabolism and Ferroptosis
Miao, X., Yue, W., Wang, J., Chen, J., Qiu, L., Paerhati, H., Zhou, Q., Li, P., Wu, A., & Zhang, M. (2025) · Current Neuropharmacology · doi:10.2174/011570159x417328250908080404 · Cited by 6
Astrocyte‐Specific Nrf2 Expression Transforms Neurotoxic Reactive Astrocytes to Neuroprotective Phenotype in 3xTg ‐ AD Mice
Guo, S., Wei, F., Sun, H., Jin, H., Cheng, W., Fu, C., Wang, H., & Yin, Y. (2025) · Glia · doi:10.1002/glia.70087 · Cited by 5
Microglial, astrocytic, oligodendrocyte, B-/T-cell and neutrophil dysregulation in neuroinflammation of Alzheimer's disease and related dementias
Singh, A. S., Naqvi, A. R., & Chanu, M. T. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.01.050 · Cited by 7
Multidisciplinary convergence drives next-generation drug discovery: A new paradigm
Lehn, J., Chen, S., Lu, J., & Chan, A. S. C. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100002 · Cited by 5
Signature of paraoxonases in the altered redox homeostasis in Alzheimer's disease
Beggiato, S., Ferrara, F., Romani, A., Cassano, T., Trentini, A., Valacchi, G., Cervellati, C., & Ferraro, L. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110839 · Cited by 6
Heart-brain mapping: Cardiac atrial function is associated with distinct cerebral regions with high free water in older adults
Ji, F., Wei, J. L. K., Leng, S., Zhong, L., Tan, R., Gao, F., Ng, K. K., Leong, R. L. F., Pasternak, O., Chee, M. W. L., et al. (2024) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x241229581 · Cited by 6
Randomized controlled trial of Bushen Yinao pill combined with conventional therapy on intestinal flora and cognitive function in older patients with Alzheimer's disease
Wang, W., Zhang, J., & Li, C. (2024) · The International Journal of Psychiatry in Medicine · doi:10.1177/00912174241290962 · Cited by 6
Semaphorin 3s signaling in the central nervous system: Mechanisms and therapeutic implication for brain diseases
Lu, Y.-P., Lu, Y.-P., Wu, Z., Han, C., Jin, Y.-Z., Han, J.-M., Chen, S.-Y., Teng, F., Han, F., Liu, X.-X., et al. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108800 · Cited by 5
Uncovering critical transitions and molecule mechanisms in disease progressions using Gaussian graphical optimal transport
Hua, W., Cui, R., Yang, H., Zhang, J., Liu, C., & Sun, J. (2025) · Communications Biology · doi:10.1038/s42003-025-07995-z · Cited by 5
The Etiology of Rapidly Progressive Dementia: A 3-Year Retrospective Study in a Tertiary Hospital in China
Shi, Q., Liu, W., Liu, F., Zeng, Y., Chen, S.-F., Chen, K., Yu, J., & Huang, Y. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240079 · Cited by 6
Current status of prevention strategies adapted for Alzheimer's disease
Singh, A., Sethi, P., Ghosh, S., Singh, D. K. K., Rohatgi, S., Singh, P. K., & Sinha, J. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15540-6.00004-5 · Cited by 5
Functional border-associated macrophages limit Alzheimer’s Disease progressionPreprint
Adler, D. I., Pinheiro-Rosa, N., Millet, A., Gajic, Z. Z., Cheng, E., Gamallo‐Lana, B., Morizawa, Y. M., Klann, E., Gan, W., Mar, A. C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.31.703045 · Cited by 8
Perceptions of key informant neurologists before implementing anti-amyloid drugs in the Spanish departments of neurology
Matías‐Guiu, J. A., Álvarez‐Sabín, J., Botia, E., Naranjo, I. C., Castellanos, M., Frank, A., Íñiguez, C., Jiménez-Hernández, M. D., Jiménez‐Jiménez, F. J., Laínez, J. M., et al. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241284312 · Cited by 4
Lipid metabolism in Alzheimer’s disease
Zhang, J., & Sima, J. (2024) · Aging Research · doi:10.26599/agr.2025.9340037 · Cited by 4
PIWI-interacting RNAs in neurological and neuropsychiatric disorders and potential for clinical development
Beatini, S., Rosa, L. L., Giantomasi, L., & Tonelli, D. D. P. (2025) · Brain Organoid and Systems Neuroscience Journal · doi:10.1016/j.bosn.2025.06.003 · Cited by 4
Novel fungal metabolites as dual cholinesterase inhibitors: A computational approach for Alzheimer’s disease therapy
Masum, M. H. U., Lokman, S. M., Parvin, R., Rahman, M. S., Chowdhury, E. H., Chamonara, K., Chowdhury, S., Mahdeen, A. A., & Khatun, M. M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326219 · Cited by 4
The Janus face of CaMKII: from memory consolidation to neurotoxic switch in Alzheimer’s disease
Tang, L., Liu, F., Sun, X., Yang, J., Liu, Y., Pan, X., Hao, L., Lou, F., & Su, J. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04160-7 · Cited by 5
Inhibition of Hippo Signaling Through Ablation of Lats1 and Lats2 Protects Against Cognitive Decline in 5xFAD Mice via Increasing Neuronal Resilience Against Ferroptosis
Evans, R. C., Dar, N. J., Chen, L., Na, R., O’Connor, J. C., Jiang, J., Zheng, S., & Ran, Q. (2025) · Aging Cell · doi:10.1111/acel.70218 · Cited by 4
A Flexible Bioresorbable Implantable Sensor for Wireless Dynamic Monitoring of H 2 O 2 Enabled by Pt‐Decorated MoO 3‐ x Nanozyme
Bi, H., Wang, Z., Sheng, H., Shang, M., Hu, J., Guo, C., Wan, D., Li, F., Yue, Q., Su, Q., et al. (2025) · Small · doi:10.1002/smll.202508861 · Cited by 4
Microglia-mediated protection against Alzheimer’s disease pathology and detrimental effects in white matter revealed by Ptpn6 deletion
Etxeberría, A., Lee, S.-H., Kuhn, J., Callow, M. G., Novikova, G., Fortin, J., Choy, M. K., Xie, L., Imperio, J., Vito, S., et al. (2026) · Neuron · doi:10.1016/j.neuron.2026.02.023 · Cited by 4
Plasma Insulin Predicts Early Amyloid-β Pathology Changes in Alzheimer’s Disease
Chen, Y., Initiative, A. D. N., Wang, Z.-B., Liu, X., & Mao, Z. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240289 · Cited by 4
Management of MCI in the Outpatient Setting
Abramowitz, A., & Weber, M. (2024) · Current Psychiatry Reports · doi:10.1007/s11920-024-01514-3 · Cited by 3
Acupuncture as a Complementary Therapy for Alzheimer’s Disease
Li, H., Xiang, Q., Ren, R., & Wang, G. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231250 · Cited by 4
A Self‐Reinforced “Microglia Energy Modulator” for Synergistic Amyloid‐β Clearance in Alzheimer's Disease Model
Ma, M., Wang, J., Guo, K., Zhong, W., Cheng, Y., Lin, L., & Zhao, Y. (2024) · Angewandte Chemie · doi:10.1002/ange.202420547 · Cited by 4
Alzheimer’s disease and antibody-mediated immune responses to infectious diseases agents: a mendelian randomization study
Zhang, J., Wang, M., Wang, D., Deng, L., & Yao, P. (2025) · Hereditas · doi:10.1186/s41065-024-00358-4 · Cited by 4
Closing the gap in dementia research by community-based cohort studies in the Chinese population
Zhou, X., Xiao, Z., Wu, W., Chen, Y., Yuan, C., Leng, Y., Yao, Y., Zhao, Q., Albert Hofman, D., Brunner, E. J., et al. (2025) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2025.101465 · Cited by 4
CSF proteomics of semorinemab Alzheimer’s disease trials identifies cell-type specific signatures
Abdel‐Haleem, A. M., Casavant, E., Tóth, B. I., Teng, E., Monteiro, C., Pandya, N. J., Glock, C., Hoogenraad, C. C., Friedman, B. A., Yeh, F. L., et al. (2025) · Brain · doi:10.1093/brain/awaf200 · Cited by 8
Financial Incentives to Increase Diversity of Older Participants in a Memory Concerns Registry
Jacobson, M., Molina‐Henry, D. P., Chang, T., Jimenez‐Maggiora, G. A., Pramanik, R., Shah, S. B., & Aisen, P. S. S. (2025) · JAMA Health Forum · doi:10.1001/jamahealthforum.2025.2273 · Cited by 4
Guardians of memory: The urgency of early dementia screening in an aging society
Hu, X., Ma, Y., Karako, K., Song, P., Tang, W., & Xia, Y. (2024) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2024.01026 · Cited by 7
tPA supplementation preserves neurovascular and cognitive function in Tg2576 mice
Uekawa, K., Anfray, A., Ahn, S. J., Casey, N., Seo, J., Zhou, P., Iadecola, C., & Park, L. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13878 · Cited by 4
The criteria used to rule out mild cognitive impairment impact dementia incidence rates in subjective cognitive decline
Whitfield, T. J., Chouliaras, L., Morrell, R., Rubio, D., Radford, D., Marchant, N. L., & Walker, Z. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01516-6 · Cited by 4
Revisiting capsaicin and nonivamide: Their analogs exert strong inhibitory activity against cholinesterases
Heise, N. V., Quast, J., & Csük, R. (2024) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2024.100200 · Cited by 4
GNG5 is a novel regulator of Aβ42 production in Alzheimer’s disease
Li, C., Yang, Y., Luo, S., Qiu, W., Wang, X., & Ge, W. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07218-z · Cited by 4
Hippocampal Synaptic Plasticity: Integrating Memory and Anxiety Impairments in the Early Stages of Alzheimer’s Disease
Good, M. A., & Bannerman, D. M. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_565 · Cited by 4
Proposed biological definitions of Parkinson's disease confuse understanding without delivering meaningful advances
Cardoso, F., & Schmidt, P. N. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x241308482 · Cited by 4
NMR Metabolomic Profiling of Differentiated SH-SY5Y Neuronal Cells: Amyloid-β Toxicity and Protective Effects of Galantamine and Lycorine
Kola, A., Costanti, F., Kahfi, J., Emwas, A.-H. M., Jaremko, M., & Valensin, D. (2025) · Cells · doi:10.3390/cells14070525 · Cited by 4
Prediction of disease progression in individuals with subjective cognitive decline using brain network analysis
Deng, S., Tan, S., Song, X., Lin, X., Yang, K., Li, X., & Initiative, A. D. N. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14859 · Cited by 3
HDL ‐Apolipoprotein in Alzheimer's Disease Revisited: From Periphery to CNS
Huang, Y., Tang, J., Chen, G., Wu, Q., Wang, Y., Chen, J., Chen, S., Liu, J., & Huang, X. (2025) · Aging Medicine · doi:10.1002/agm2.70008 · Cited by 3
A mass-producible macaque model displays a durable Alzheimer-like cognitive deficit and hallmark amyloid-β/tau/neurofilament light chain pathologies
He, F., Shi, W.-J., Liu, W., Fan, J.-X., He, Z., Zhang, Y., Xiao, J., Ruan, W., Gai, Y., Zhang, H., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251334316 · Cited by 4
Thwarting amyloidosis: IL-17 as a disease modifier along the gut/brain axis
Self, W. K., & Holtzman, D. M. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194443 · Cited by 3
Self-citation
Healthy lifestyle mitigates the adverse association of particulate matter with cognitive function: a 10-year longitudinal analysis of older adults in China
Zhao, Q., Feng, Q., Hilal, S., & Seow, W. J. (2025) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaf171 · Cited by 3
Associations between peripheral nerve stimulation and cognitive performance: insights from healthy individuals and various disease pathologies
Liu, X., Yang, C., Wang, X., Wang, Z., Liao, H., Liu, H., Zhang, M., Zhang, L., & Wang, H. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1518198 · Cited by 3
Measuring alignment between the ADRC UDS data elements, FDA, and EHR data standards
Wang, Z., Torres, K., Foster, H., Walker, G., Garza, M. Y., Palmer, A., LeRoy, E. C., Facile, R., Kirwin, M. A., & Zozus, M. N. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70628 · Cited by 3

Authors: Self, W. K., & Holtzman, D. M.
Affiliations: Washington University in St. Louis (US)
Corresponding author: Holtzman, David M.
ORCID: Self, Wade K.
Holtzman, David M.
Venue: Nature Medicine
Publisher: Springer Science and Business Media LLC
Published: 2023-09
Volume: 29
Issue: 9
Pages: 2187-2199
ISSN: 1078-8956 (ISSN-L)
1546-170X
DOI: 10.1038/s41591-023-02505-2
OpenAlex: W4386437808
Cited by: 381
References: 159
Citations by year: 2026: 91 · 2025: 140 · 2024: 134 · 2023: 15
FWCI: 14.09
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (RF1NS090934, RF1AG047644)
U.S. Department of Health & Human Services | NIH | National Institute on Aging (U19AG069701)
Cure Alzheimer’s Fund
JPB Foundation
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords: Alzheimer's disease, biomarkers, amyloid, tau protein, neuroinflammation, anti-amyloid antibodies, disease-modifying therapy, neuroimaging, fluid biomarkers, pathological staging, cognitive decline, therapeutic target, dementia
MeSH terms: Alzheimer Disease, Humans, Technology, Neuroimaging, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Emerging diagnostics and therapeutics for Alzheimer disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks